Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.

ABSTRACT: Patients with rare solid tumors treated on early phase trials experience toxicities from their tumors and treatments. However, limited data exist to describe the detailed symptom burden suffered by these patients, particularly those with rare solid tumors treated with immunotherapy. We performed a prospective longitudinal study to capture patient-reported symptom burden. Patients completed the validated MD Anderson Symptom Inventory (MDASI)-Immunotherapy with 20 symptoms including 7 immunotherapy-specific items and 6 interference items at baseline and weekly thereafter for up to 9 weeks. Symptoms and interference were rated on 0-10 scales (0 = none or no interference, 10 = worst imaginable or complete interference). Group-based trajectory modelling determined higher and lower symptom group

SUBMITTER: Mendoza TR 

PROVIDER: S-EPMC9399082 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature